Concomitant Intake of Coca-Cola to Manage the Drug-Drug Interaction Between Velpatasvir and Omeprazole Studied in Healthy Volunteers
Minou van Seyen, Angela Colbers, Evertine J Abbink, Joost P H Drenth, David M Burger, Minou van Seyen, Angela Colbers, Evertine J Abbink, Joost P H Drenth, David M Burger
Abstract
We aimed to evaluate the effect of the acid beverage Coca-Cola on the pharmacokinetics of velpatasvir (VEL) when given with omeprazole. This was an open-label, randomized, crossover trial in 11 healthy adults. A single dose of sofosbuvir/velpatasvir (SOF/VEL) 400/100 mg was administered alone (reference) or with omeprazole 40 mg once daily with water (intervention I); in the intervention II arm, omeprazole 40 mg was combined with 250 mL of Coca-Cola. Geometric mean ratios (GMRs) were calculated for VEL area under the concentration-time curve from zero to infinity (AUC0-inf ) and maximum plasma concentration (Cmax ). VEL exposure was reduced by 26.7% when SOF/VEL was coadministered with omeprazole vs. reference: GMRs (90% confidence interval (CI)) were 73.3% (55.6-96.8) and 69.1% (52.3-91.2) for AUC0-inf and Cmax , respectively. Intake of SOF/VEL with Coca-Cola compensated for the interaction with omeprazole and resulted in a higher VEL exposure. GMRs (90% CI) were 161.6% (122.4-213.3) for AUC0-inf and 143.9% (109.0-190.0) for Cmax . Therefore, Coca-Cola can be used to overcome the drug-drug interaction between VEL and omeprazole.
Trial registration: ClinicalTrials.gov NCT03513393.
Conflict of interest statement
D.B. and J.D. have received research grants from Gilead, the manufacturer of velpatasvir; J.D. has been part of an advisory board for Gilead. All other authors declared no competing interests for this work.
© 2019 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.
Figures
References
- European Medicines Agency (EMA) . Epclusa: Assessment Report 2016. <>.
- Mogalian, E. et al Preclinical pharmacokinetics and first‐in‐human pharmacokinetics, safety, and tolerability of velpatasvir, a pangenotypic hepatitis C virus NS5A inhibitor, in healthy subjects. Antimicrob. Agents Chemother. 61 pii: e02084‐16 (2017).
- US Food and Drug Administration (FDA) . Epclusa: Chemistry Review(s) <> (2016).
- Miner, P. Jr , Katz, P.O. , Chen, Y. & Sostek, M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five‐way crossover study. Am. J. Gastroenterol. 98, 2616–2620 (2003).
- Mogalian, E. et al Drug–Drug Interaction Profile of Sofosbuvir/Velpatasvir Fixed‐Dose Combination International Liver Congress, Barcelona, Spain, April 13−17, 2016 (Poster FRI‐168).
- European Medicines Agency (EMA) . Epclusa: Summary of Product Characteristics <> (2016). Accessed July 3, 2018.
- Smolders, E.J. , Berden, F.A. , de Kanter, C.T. , Kievit, W. , Drenth, J.P. & Burger, D.M. The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug–drug interactions. United European Gastroenterol. J. 5, 648–657 (2017).
- Tapper, E.B. et al Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real‐world cohort study. Hepatology 64, 1893–1899 (2016).
- Lange, D. , Pavao, J.H. , Wu, J. & Klausner, M. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. Drug Interact. 37, 535–540 (1997).
- van Leeuwen, R.W. et al Influence of the acidic beverage cola on the absorption of erlotinib in patients with non‐small‐cell lung cancer. J. Clin. Oncol. 34, 1309–1314 (2016).
- Chin, T.W. , Loeb, M. & Fong, I.W. Effects of an acidic beverage (Coca‐Cola) on absorption of ketoconazole. Antimicrob Agents Chemother. 39, 1671–1675 (1995).
- US Food and Drug Administration (FDA) . Epclusa: Clinical pharmacology and biopharmaceutics review(s) (2016).
- Walravens, J. , Brouwers, J. , Spriet, I. , Tack, J. , Annaert, P. & Augustijns, P. Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations. Clin. Pharmacokinet. 50, 725–734 (2011).
- AstraZeneca Losec . Summary of Product Characteristics (2011).
- Lawitz, E. et al A phase 1, randomized, dose‐ranging study of GS‐5816, a once‐daily NS5A inhibitor, in patients with genotype 1‐4 hepatitis C virus. J. Viral Hepat. 22, 1011–1019 (2015).
- Esteban, R. et al (eds.) Sofosbuvir/velpatasvir is effective and safe in patients with concomitant proton pump inhibitor use in clinical studies. AASLD The Liver Meeting, San Francisco, CA, November 9−13, 2018 (Poster 0702).
- Tapper, E.B. et al Real‐world effectiveness for 12 weeks of ledipasvir‐sofosbuvir for genotype 1 hepatitis C: the Trio Health study. J. Viral Hepat. 24, 22–27 (2017).
- Wijarnpreecha, K. , Chesdachai, S. , Thongprayoon, C. , Jaruvongvanich, V. , Ungprasert, P. & Cheungpasitporn, W. Efficacy and safety of direct‐acting antivirals in hepatitis C virus‐infected patients taking proton pump inhibitors. J. Clin. Transl. Hepatol. 5, 327–334 (2017).
- Reddy, A. , Norris, D.F. , Momeni, S.S. , Waldo, B. & Ruby, J.D. The pH of beverages in the United States. J. Am. Dental Assoc. (1939) 147, 255–263 (2016).
- van Seyen, M. , de Graaff Teulen, M.J.A. , van Erp, N.P. & Burger, D.M. Quantification of second generation direct‐acting antivirals daclatasvir, elbasvir, grazoprevir, ledipasvir, simeprevir, sofosbuvir and velpatasvir in human plasma by UPLC‐MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1110–1111, 15–24 (2019).
- Furuta, T. et al CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin. Pharmacol. Ther. 65, 552–561 (1999).
Source: PubMed